Segment Data (Schedule of Segment Reporting Information by Business Segment) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended				9 Months Ended
	Jun. 27, 2014		Jun. 28, 2013		Jun. 27, 2014		Jun. 28, 2013
Net sales	$ 653.1		$ 570.0		$ 1,751.1		$ 1,659.3
Operating income (loss)	(4.4)		(0.6)		72.4		89.7
Intangible asset amortization	(51.6)		(8.9)		(75.9)		(26.6)
Restructuring and related charges, net	(24.2)		(12.1)		(54.0)		(20.0)
Separation costs	(1.8)		(44.2)		(6.6)		(70.6)
Restructuring related accelerated depreciation	0.4		0.8		0.5		2.1
Specialty Pharmaceuticals
Restructuring and related charges, net	(11.8)		(7.0)		(14.5)		(13.6)
Global Medical Imaging
Restructuring and related charges, net	(10.6)		(5.1)		(37.2)		(6.4)
Operating Segments
Net sales	641.4	[1]	556.5	[1]	1,716.2	[1]	1,619.9	[1]
Operating income (loss)	136.8		108.3		370.4		316.3
Operating Segments | Specialty Pharmaceuticals
Net sales	414.3		308.6		1,048.1		913.2
Operating income (loss)	125.6		94.8		344.5		234.8
Operating Segments | Global Medical Imaging
Net sales	227.1		247.9		668.1		706.7
Operating income (loss)	11.2		13.5		25.9		81.5
Corporate, Non-Segment
Net sales	11.7	[2]	13.5	[2]	34.9	[2]	39.4	[2]
Corporate and allocated expenses	(63.6)	[3]	(43.7)	[3]	(161.5)	[3]	(109.4)	[3]
Intangible asset amortization	(51.6)		(8.9)		(75.9)		(26.6)
Restructuring and related charges, net	(24.2)	[4]	(12.1)	[4]	(54.0)	[4]	(20.0)	[4]
Separation costs	$ (1.8)		$ (44.2)		$ (6.6)		$ (70.6)

[1] Amounts represent sales to external customers.

[2] Represents products that were sold to Covidien, our former parent company, which is discussed in Note 14.

[3] Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.

[4] Includes restructuring-related accelerated depreciation of $0.4 million and $0.8 million for the three months ended June 27, 2014 and June 28, 2013, respectively, and $0.5 million and $2.1 million for the nine months ended June 27, 2014 and June 28, 2013, respectively.